Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
The closing of the offering is expected to occur on or about September 19, 2023, subject to the satisfaction of customary closing conditions.
- The closing of the offering is expected to occur on or about September 19, 2023, subject to the satisfaction of customary closing conditions.
- The gross proceeds to the Company from the offering are expected to be approximately $1.33 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
- The offering of the ADSs (or ADS equivalents) in the registered direct offering is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
- A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC.